Theriva Biologics Licenses SYN-020 for $38M, Advances VCN-01 Trials
Event summary
- Licensed SYN-020 to Rasayana Therapeutics for up to $38M in milestones plus royalties.
- VCN-01 Phase 3 trial design for pancreatic ductal adenocarcinoma (PDAC) approved by EMA.
- Cash position of $15.2M as of February 26, 2026, providing runway into Q1 2027.
- General and administrative expenses increased 109% to $15.4M in 2025.
- Research and development expenses decreased 28% to $8.6M in 2025.
The big picture
Theriva Biologics is strategically pivoting by licensing non-core assets like SYN-020 to Rasayana Therapeutics, allowing it to focus on advancing its oncology pipeline, particularly VCN-01. The company's recent regulatory advancements for VCN-01 in PDAC and retinoblastoma highlight its commitment to addressing high-unmet medical needs. With a strengthened cash position, Theriva aims to navigate the challenging biotech landscape while maintaining its focus on pivotal clinical trials.
What we're watching
- Regulatory Clarity
- Whether the FDA's End-of-Phase 2 meeting in 1H 2026 will finalize the pivotal Phase 3 trial design for VCN-01 in PDAC.
- Execution Risk
- The pace at which Theriva can advance VCN-01 trials in PDAC and retinoblastoma while managing its cash runway.
- Partnership Dynamics
- How Rasayana Therapeutics' development and commercialization of SYN-020 will impact Theriva's financial performance.
Related topics